One of the most rewarding aspects of covering biotech is being able to report on the long arc of drug development, from start to finish. It’s not always good, and often, it ends badly.
But KarXT, now Cobenfy, is one of those drug stories with a happy ending. I remember talking to Steven Paul in 2019 about the results of phase 2, which was very surprising. Paul was excited about what KarXT might mean for people with schizophrenia, but he was cautious because, as he warned me at the time, clinical trials of psychiatric conditions are very difficult to replicate. Let’s wait and see what KarXT does in the Ph3 tests, he said.
Now, we know.
It’s been great following and reporting on the KarXT story all these years. From PureTech to Karuna to Bristol Myers Squibb, and now, for approval, where Cobenfy will have a meaningful impact on people living with schizophrenia.
That’s from Adam Feuerstein, who also links to StatNews:
The drug, called Cobenfy, will be sold by Bristol Myers Squibb. It was developed by biotech company Karuna Therapeutics, which Bristol acquired for $14 billion last year.
Supply is stretching, folks. And we live in a time of (potential) health advances.
Source link